Vincristine-ticlopidine-aspirin: an effective therapy in children with Kasabach-Merritt phenomenon associated with vascular tumors.
Kasabach-Merritt phenomenon (KMP) is a serious coagulopathy with severe thrombocytopenia (<10,000/mm³) that occurs in the presence of an enlarging vascular tumor such as kaposiform hemangioendothelioma (KHE) and tufted angioma (TA). The natural history and treatment of these lesions remain controversial. The authors report a KHE case and a TA case that presented with KMP, describing their successful pharmacological management with vincristine, ticlopidine, and aspirin.
Fernandez-Pineda
Israel
I
Department of Pediatric Surgery, Virgen del Rocio Children's Hospital, Sevilla, Spain. israfdez@hotmail.com
Lopez-Gutierrez
Juan Carlos
JC
Ramirez
Gema
G
Marquez
Catalina
C
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D004211:Disseminated Intravascular Coagulation / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D018324:Hemangioma, Capillary / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007223:Infant; D059885:Kasabach-Merritt Syndrome; D013988:Ticlopidine / Q000627:therapeutic use*; D016896:Treatment Outcome; D019043:Vascular Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D014750:Vincristine / Q000627:therapeutic use*
D014750:Vincristine; D013988:Ticlopidine; D001241:Aspirin